Switch theme
Sign up to access all valuation multiples
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
1987
17.6K+
LTM Revenue $28.7B
LTM EBITDA $12.3B
$154B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gilead Sciences has a last 12-month revenue (LTM) of $28.7B and a last 12-month EBITDA of $12.3B.
In the most recent fiscal year, Gilead Sciences achieved revenue of $28.8B and an EBITDA of $4.4B.
Gilead Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gilead Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.7B | XXX | $28.8B | XXX | XXX | XXX |
| Gross Profit | $24.7B | XXX | $22.5B | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $12.3B | XXX | $4.4B | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $10.4B | XXX | $10.5B | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 37% | XXX | XXX | XXX |
| Net Profit | $7.5B | XXX | $480M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $16.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Gilead Sciences's stock price is $110.
Gilead Sciences has current market cap of $137B, and EV of $154B.
See Gilead Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $154B | $137B | XXX | XXX | XXX | XXX | $6.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Gilead Sciences has market cap of $137B and EV of $154B.
Gilead Sciences's trades at 5.4x EV/Revenue multiple, and 34.7x EV/EBITDA.
Equity research analysts estimate Gilead Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gilead Sciences has a P/E ratio of 18.2x.
See valuation multiples for Gilead Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $137B | XXX | $137B | XXX | XXX | XXX |
| EV (current) | $154B | XXX | $154B | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | 12.5x | XXX | 34.7x | XXX | XXX | XXX |
| EV/EBIT | 14.8x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.2x | XXX | 285.3x | XXX | XXX | XXX |
| EV/FCF | 15.4x | XXX | 14.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGilead Sciences's last 12 month revenue growth is 1%
Gilead Sciences's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.7M for the same period.
Gilead Sciences's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gilead Sciences's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Gilead Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gilead Sciences acquired XXX companies to date.
Last acquisition by Gilead Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Gilead Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Gilead Sciences founded? | Gilead Sciences was founded in 1987. |
| Where is Gilead Sciences headquartered? | Gilead Sciences is headquartered in United States of America. |
| How many employees does Gilead Sciences have? | As of today, Gilead Sciences has 17.6K+ employees. |
| Who is the CEO of Gilead Sciences? | Gilead Sciences's CEO is Mr. Daniel P. O'Day. |
| Is Gilead Sciences publicy listed? | Yes, Gilead Sciences is a public company listed on NAS. |
| What is the stock symbol of Gilead Sciences? | Gilead Sciences trades under GILD ticker. |
| When did Gilead Sciences go public? | Gilead Sciences went public in 1992. |
| Who are competitors of Gilead Sciences? | Similar companies to Gilead Sciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Gilead Sciences? | Gilead Sciences's current market cap is $137B |
| What is the current revenue of Gilead Sciences? | Gilead Sciences's last 12 months revenue is $28.7B. |
| What is the current revenue growth of Gilead Sciences? | Gilead Sciences revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Gilead Sciences? | Current revenue multiple of Gilead Sciences is 5.4x. |
| Is Gilead Sciences profitable? | Yes, Gilead Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gilead Sciences? | Gilead Sciences's last 12 months EBITDA is $12.3B. |
| What is Gilead Sciences's EBITDA margin? | Gilead Sciences's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Gilead Sciences? | Current EBITDA multiple of Gilead Sciences is 12.5x. |
| What is the current FCF of Gilead Sciences? | Gilead Sciences's last 12 months FCF is $10.0B. |
| What is Gilead Sciences's FCF margin? | Gilead Sciences's last 12 months FCF margin is 35%. |
| What is the current EV/FCF multiple of Gilead Sciences? | Current FCF multiple of Gilead Sciences is 15.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
